ClinicalTrials.gg
Active, not recruitingNCT04077723Updated Nov 9, 2026

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

A Phase 1/2 interventional study of Englumafusp alfa and Obinutuzumab in Lymphoma, Non-Hodgkin, sponsored by Hoffmann-La Roche. Active, not recruiting at 35 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Updated Nov 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
498
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, none of them phase 3. obinutuzumab · Lymphoma, Non-Hodgkin.

Planned enrollment
2nd of 15
498 · median 41
Started
2019
the only one that year
Phase 1/2
4 of 15
1 open now
Registered
14th of 15
by date
Lead sponsor
5 of 15
Hoffmann-La Roche

Among the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, this one is the 2nd largest by planned enrollment, is the only one that started in 2019, is one of 4 in phase 1/2, and was the 14th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About obinutuzumab

obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab and in combination with glofitamab. A fixed dose of obinutuzumab (Gpt; pre-treatment) will be administered up to seven days prior to the first administration of englumafusp alfa and seven days prior to the first administration of glofitamab. This entry-into-human study is divided into a dose-escalation stage (Part I and Part II) and a dose expansion stage (Part III).

03

Conditions studied

  • Lymphoma, Non-Hodgkin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History or status of a -confirmed hematological that is expected to express CD19 and CD20; relapse after or failure to respond to at least one prior treatment regimen; no available treatment options that are expected to prolong survival (Part I and II); after or failed to respond to only one prior systemic treatment regimen (Part III)
  • Must have at least one measurable target lesion (>/= 1.5 cm) in its largest dimension by computed tomography scan
  • Able and willing to provide a fresh from a safely accessible site, per Investigator's determination, providing the participant has more than one measurable target lesion
  • (ECOG) performance status of 0 or 1, or \</= 2 for some participants in Part III
  • of >/= 12 weeks
  • Adverse events from prior anti-cancer therapy must have resolved to Grade \</= 1
  • Adequate liver, hematological, and renal function
  • Negative test results for acute or chronic virus infection
  • Negative test results for virus and
  • The and abstinence requirements are intended to prevent exposure of an embryo to the study treatment. The reliability of sexual abstinence for male and/or female enrollment eligibility needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of preventing drug exposure
  • Female participants: A female participant is eligible to participate if she is not pregnant and not breastfeeding, and if at least one of the following applies: women of non- (WONCBP); women of child bearing potential (WOCBP) who agree to remain abstinent or use two highly effective contraceptive methods with a failure rate of \<1% per year during the treatment period and for at least 18 months after obinutuzumab or 3.5 months after the last dose of englumafusp alfa, 2 months after last dose of glofitamab, or 3 months after the last dose of tocilizumab, whichever is longer. Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal occlusion/ ligation, male sexual partner who is sterilized, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices and copper intrauterine devices. Hormonal contraceptive methods must be supplemented by a barrier method; have a negative pregnancy test (blood) within the 7 days prior to the first study treatment administration
  • Male participants: During the treatment period and for at least 3 months after obinutuzumab, or 3.5 months after the last dose of englumafusp alfa, 2 months after the last dose of glofitamab, or 2 months after the last dose of tocilizumab whichever is longer, agreement to: Remain abstinent or use contraceptive measures such as a condom plus an additional contraceptive method that together result in a failure rate of \< 1% per year, with a partner who is a women of childbearing potential. With pregnant female partner, remain abstinent or use contraceptive measures such as a condom to avoid exposing the embryo; refrain from donating sperm during this same period

Exclusion criteria

Exclusion Criteria:

  • Circulating lymphoma cells, defined by out of range (high) absolute lymphocyte count (ALC) or the presence of abnormal cells in the peripheral blood signifying circulating lymphoma cells (for some participants in Part III, ALC only)
  • Participants with acute bacterial, viral, or fungal infection at baseline, confirmed by a positive blood culture within 72 hours prior to obinutuzumab infusion or by clinical judgment in the absence of a positive blood culture
  • Participants with known active infection, or reactivation of a latent infection, whether bacterial, viral fungal, mycobacterial, or other pathogens (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics
  • Pregnant or breast-feeding or intending to become pregnant during the study
  • Prior treatment with systemic immunotherapeutic agents, including, but not limited to, radio-immunoconjugates, antibody-drug conjugates, immune/cytokines or monoclonal antibodies within 4 weeks or five half-lives of the drug, whichever is shorter, before obinutuzumab infusion
  • History of treatment-emergent immune-related AEs associated with prior immunotherapeutic agents and auto-immune disease
  • Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with any other or approved anti-cancer agent within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to obinutuzumab infusion
  • Prior solid organ transplantation
  • Prior stem cell transplant
  • Autologous stem cell transplant within 100 days prior to obinutuzumab infusion
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy and confirmed progressive multifocal leukoencephalopathy
  • Current or past history of central nervous system (CNS) lymphoma and CNS disease
  • Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including diabetes mellitus, history of relevant pulmonary disorders and known diseases
  • Major surgery or significant traumatic injury \< 28 days prior to the Gpt infusion or anticipation of the need for major surgery during study treatment
  • Participants with another invasive in the last 2 years
  • Significant cardiovascular disease
  • Administration of a live, attenuated vaccine within 4 weeks before Gpt infusion or anticipation that such a will be required during the study
  • Received systemic medications (including but not limited to cyclohosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within two weeks prior to Gpt, with the exception of treatment \<=25 mg/day of prednisone or equivalent, however there must be documentation that the participant was on a stable dose of at least a 2-week duration prior to Gpt infusion. Inhaled and topical steroids are permitted
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
498 participants (estimated)

Study arms

  • Experimental
    Part I

    Combination Dose-Escalation: Mixed r/r NHL participants will receive a fixed dose of obinutuzumab up to seven days prior to first administration of englumafusp alfa. Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab in a three-weekly schedule (Q3W).

    Drug: Englumafusp alfa · Drug: Obinutuzumab · Drug: Tocilizumab

  • Experimental
    Part II

    Combination Dose-Escalation: Mixed r/r participants and participants with mixed r/r mantle cell lymphoma (MCL) and Richters transformation will receive a fixed dose of obinutuzumab seven days prior to first administration of englumafusp alfa. Englumafusp alfa will be administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).

    Drug: Englumafusp alfa · Drug: Obinutuzumab · Drug: Glofitamab · Drug: Tocilizumab

  • Experimental
    Part III

    Dose-Expansion Stage: Participants with r/r diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), high-grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL), and DLBCL arising from FL (transformed FL) will receive englumafusp alfa administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).

    Drug: Englumafusp alfa · Drug: Obinutuzumab · Drug: Glofitamab · Drug: Tocilizumab

Interventions

  • DrugEnglumafusp alfa

    Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).

    Also known as: A CD19 Targeted 4-1BB Ligand; RO7227166

  • A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I). A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III).

    Also known as: Gpt, RO5072759, Gazyva, Gazyvaro

  • A fixed dose of glofitamab will be administered Q3W in combination with englumafusp alfa in Part II and Part III

    Also known as: CD20-TCB, RO7082859

  • Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).

    Also known as: Actemra, RoActemra

06

What researchers measure

Primary outcomes

  1. Nature and frequency of dose-limiting toxicities (DLTs)

    Time frame: 28 days in Part I and Part II

  2. Proportion of Participants with Adverse Event (AE)

    Incidence, nature, and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

    Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months

  3. Overall Response Rate (ORR)

    Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months

  4. Disease Control Rate (DCR)

    Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months

  5. Duration of Response (DOR)

    Time frame: After end of Study approximately every 3 months until death, loss to follow-up or study termination

  6. Progression-free Survival (PFS)

    Time frame: After end of Study approximately every 3 months until death, loss to follow-up or study termination

  7. Overall Survival (OS)

    Time frame: After end of Study approximately every 3 months until death, loss to follow-up or study termination

  8. Complete Response (CR)

    Time frame: Part III: Up to 9 months or up to 18 months

Secondary outcomes

  1. Total exposure (area under the concentration time curve [AUC]) of englumafusp alfa in combination with obinutuzumab and glofitamab

    Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months

  2. Maximum serum concentration (peak concentration, Cmax) of englumafusp alfa in combination with obinutuzumab and glofitamab

    Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months

  3. Minimum serum concentration (trough concentration, Cmin) of englumafusp alfa in combination with obinutuzumab and glofitamab

    Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months

  4. Clearance (CL) of englumafusp alfa in combination with obinutuzumab and glofitamab

    Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months

  5. Volume of distribution of steady state (Vss) and half-life (t1/2) of englumafusp alfa in combination with obinutuzumab and glofitamab

    Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months

  6. ORR

    Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months

  7. DCR

    Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months

  8. DOR

    Time frame: After end of Study approximately every 3 months until death, loss to follow-up or study termination

  9. PFS

    Time frame: After end of Study approximately every 3 months until death, loss to follow-up or study termination

  10. OS

    Time frame: After end of Study approximately every 3 months until death, loss to follow-up or study termination

  11. Proportion of Participants with Adverse Event (AE)

    Incidence, nature, and severity of AEs graded according to the NCI CTCAE v5.0

    Time frame: After end of Study approximately every 3 months until death, loss to follow-up or study termination

  12. Total exposure (area under the concentration time curve [AUC]) of englumafusp alfa in combination with glofitamab

    Time frame: Part III: Up to 9 months or up to 18 months

  13. Maximum serum concentration (peak concentration, Cmax) of englumafusp alfa in combination with glofitamab

    Time frame: Part III: Up to 9 months or up to 18 months

  14. Minimum serum concentration (trough concentration, Cmin) of englumafusp alfa in combination with glofitamab

    Time frame: Part III: Up to 9 months or up to 18 months

  15. Clearance (CL) of englumafusp alfa in combination with glofitamab

    Time frame: Part III: Up to 9 months or up to 18 months

  16. Volume of distribution of steady state (Vss) and half-life (t1/2) of englumafusp alfa in combination with glofitamab Part I/II/III

    Time frame: Part III: Up to 9 months or up to 18 months

  17. T-cell and Natural killer (NK)-cell status in blood, using markers of T and NK-cell lineage, function and activation including, but not limited to, CD3, CD8, 41BB, and Ki67 expression

    Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months

  18. B-cell reduction in blood and tumor tissue

    Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months

  19. Change from Baseline in englumafusp alfa Anti-Drug Antibody (ADA) Titer

    Time frame: Part 1: Up to 24 months; Part ll/lll: Up to 18 months

  20. Time to First Complete Response (TFCR)

    Time frame: Up to 18 months

  21. Time to First Overall Response (TFOR)

    Time frame: Up to 18 months

  22. Duration of Complete Response (DOCR)

    Time frame: Part III: Up to 9 months or up to 18 months

  23. Change from Baseline in Physical Function, Role Function, and Health-Related Quality of Life (HRQoL) Based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    Time frame: Part III: Up to 9 months or up to 18 months

  24. Change from Baseline in Physical Function, Role Function, and HRQoL According to the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Lymphoma Scale

    Time frame: Part III: Up to 9 months or up to 18 months

07

Study locations

35 sites
08

References and documents

Publications

  • Hutchings M, Dickinson M, Gritti G, Carlo-Stella C, Townsend W, Bosch F, Bartlett NL, Cartron G, Ghesquieres H, Houot R, Walter H, Offner F, Dimier N, Jamois C, Herter S, Keelara A, Wilson S, Gallien J, Hinton H, Gonzalez-Albo IP, Korfi K, Kazantzidis G, Wasmer MH, Lechner K, Morschhauser F. Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial. Nat Med. 2026 Jul 16. doi: 10.1038/s41591-026-04533-0. Online ahead of print. PubMed 42463852 ↗

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2019 (actual). Primary completion is estimated for Dec 2026, 88 months after the start.

Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's planned 88 months is above that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Mar 2027 → Dec 2026 and completion Mar 2027 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2019
First posted
Sep 4, 2019
StartActual
Aug 13, 2019
Primary completionEst.
Dec 28, 2026was Mar 2027
CompletionEst.
Dec 28, 2026was Mar 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 31, 2027→Dec 28, 2026
Nov 9, 2026
Study completion
Mar 31, 2027→Dec 28, 2026
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Mar 31, 2027→Dec 28, 2026
    Study completion Mar 31, 2027→Dec 28, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04077723
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 4, 2019
Start date
Aug 13, 2019
Primary completion
Dec 28, 2026 (estimated)
Completion
Dec 28, 2026 (estimated)
Last update
Nov 9, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion